DBV Technologies S.A. (EPA:DBV)
France · Delayed Price · Currency is EUR 2.498
+0.004 (0.16%)
Aug 21, 2026, 5:35 PM CET
DBV Technologies Revenue
DBV Technologies had revenue of $700.00K USD in the quarter ending June 30, 2026, a decrease of -53.33%. This brings the company's revenue in the last twelve months to $4.37M, up 29.72% year-over-year. In the year 2025, DBV Technologies had annual revenue of $5.64M with 35.77% growth.
Revenue (ttm)
$4.37M
Revenue Growth
+29.72%
P/S Ratio
167.69
Revenue / Employee
$25.73K
Employees
170
Market Cap
739.20M EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.64M | 1.49M | 35.77% |
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | 14.71M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 142.94M |
| Genfit | 70.85M |
| Cellectis | 55.86M |
| Nanobiotix | 32.59M |
| MedinCell | 24.28M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Inventiva | 6.76M |
DBV Technologies News
- 23 days ago - DBVT Plans $50M ADS Share Issuance Amid Unprofitable Growth Phase - GuruFocus
- 23 days ago - DBV Technologies S.A.: DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq - Finanz Nachrichten
- 23 days ago - DBV Technologies announces sale of $50M of ADSs through ATM program - TheFly
- 23 days ago - DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq - GlobeNewsWire
- 27 days ago - DelveInsight Business Research, LLP: Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight - Finanz Nachrichten
- 5 weeks ago - DBVT Secures $150M Shelf Registration to Support Future Growth - GuruFocus
- 5 weeks ago - DBV Technologies S.A.: DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - Finanz Nachrichten
- 5 weeks ago - DBV Technologies announces $150M at-the-market offering - TheFly